{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:33:07Z","timestamp":1793370787890,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clinbiochem.2026.111131","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T15:34:02Z","timestamp":1777995242000},"page":"111131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Persistent red fluorescence interference in anti-PLA2R indirect immunofluorescence assays associated with liposomal doxorubicin"],"prefix":"10.1016","volume":"144","author":[{"given":"St\u00e9phane","family":"Lopes-Paciencia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas J.","family":"Caron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charleen","family":"Salesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Claveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Philippe","family":"Laurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2833-6921","authenticated-orcid":false,"given":"Karim","family":"Benkirane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2026.111131_b0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.clinbiochem.2026.111131_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/genes14071343","article-title":"The Role of PLA2R in primary membranous nephropathy: do we still need a Kidney Biopsy?","volume":"14","author":"McDonnell","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.clinbiochem.2026.111131_b0015","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad228","article-title":"Novel biomarkers and pathophysiology of membranous nephropathy: PLA2R and beyond","volume":"17","author":"Murtas","year":"2024","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.clinbiochem.2026.111131_b0020","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1681\/ASN.2021101384","article-title":"Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy","volume":"33","author":"Gao","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinbiochem.2026.111131_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1036249","article-title":"Membranous nephropathy: clearer pathology and mechanisms identify potential strategies for treatment","volume":"13","author":"Chung","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clinbiochem.2026.111131_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.593288","article-title":"Autoantibodies in the diagnosis, monitoring, and treatment of membranous nephropathy","volume":"12","author":"Tesar","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clinbiochem.2026.111131_b0035","doi-asserted-by":"crossref","DOI":"10.1177\/20543581211052729","article-title":"Qualitative and quantitative dosage of the anti M-Type phospholipase A2 receptor autoantibody: one-year experience in Quebec's Reference Center","volume":"8","author":"Leclerc","year":"2021","journal-title":"Can. J. Kidney Health Dis."},{"key":"10.1016\/j.clinbiochem.2026.111131_b0040","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1021\/cr900343z","article-title":"Fluorescence lifetime measurements and biological imaging","volume":"110","author":"Berezin","year":"2010","journal-title":"Chem. Rev."},{"key":"10.1016\/j.clinbiochem.2026.111131_b0045","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/cyto.990130604","article-title":"Quantification by laser scan microscopy of intracellular doxorubicin distribution","volume":"13","author":"de Lange","year":"1992","journal-title":"Cytometry"},{"key":"10.1016\/j.clinbiochem.2026.111131_b0050","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/jat\/bkaa016","article-title":"Isotonitazene quantitation and metabolite discovery in authentic forensic casework","volume":"44","author":"Krotulski","year":"2020","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.clinbiochem.2026.111131_b0055","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3109\/02841868909092323","article-title":"Pharmacokinetics of anthracyclines","volume":"28","author":"Eksborg","year":"1989","journal-title":"Acta Oncol."},{"key":"10.1016\/j.clinbiochem.2026.111131_b0060","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2165\/11207510-000000000-00000","article-title":"Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma","volume":"71","author":"Duggan","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.clinbiochem.2026.111131_b0065","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40259-013-0070-1","article-title":"Pegylated liposomal doxorubicin: a guide to its use in various malignancies","volume":"27","author":"Lyseng-Williamson","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.clinbiochem.2026.111131_b0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/cyto.990130109","article-title":"Fixation of mammalian cells for flow cytometric evaluation of DNA content and nuclear immunofluorescence","volume":"13","author":"Schimenti","year":"1992","journal-title":"Cytometry"},{"key":"10.1016\/j.clinbiochem.2026.111131_b0075","first-page":"84","article-title":"Doxorubicin, DNA torsion, and chromatin dynamics","volume":"1845","author":"Yang","year":"2014","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912026000597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912026000597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:54:33Z","timestamp":1793368473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912026000597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":15,"alternative-id":["S0009912026000597"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2026.111131","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent red fluorescence interference in anti-PLA2R indirect immunofluorescence assays associated with liposomal doxorubicin","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2026.111131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111131"}}